microRNA management of NK-cell developmental and functional programs

被引:46
|
作者
Leong, Jeffrey W. [1 ]
Sullivan, Ryan P. [1 ]
Fehniger, Todd A. [1 ]
机构
[1] Washington Univ, Sch Med, Dept Med, Div Oncol, St Louis, MO 63110 USA
关键词
Activation; Development; Lymphocyte; microRNA; NK cell; NATURAL-KILLER-CELLS; ACTIVATION; EXPRESSION; MIR-155; INNATE; IDENTIFICATION; CYTOTOXICITY; TRANSLATION; HOMEOSTASIS; REGULATORS;
D O I
10.1002/eji.201444798
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
NK cells are innate lymphoid cells that are critical for host defense against infection, and mediate anti-tumor responses. MicroRNAs (miRNAs) are a large family of small noncoding RNAs that target the 3' untranslated region (UTR) of mRNAs, thereby attenuating protein translation. The expression of miRNAs within human peripheral blood and mouse splenic NK cells has been cataloged, with the majority of the miRNA sequence pool represented in the top 60 most abundantly expressed miRNAs. Global miRNA deficiency within NK cells has confirmed their critical role in NK-cell biology, including defects in NK-cell development and altered functionality. Studies using gain-and loss-of-function of individual miRNAs in NK cells have demonstrated the role of specific miRNAs in regulating NK-cell development, maturation, and activation. miRNAs also regulate fundamental NK-cell processes including cytokine production, cytotoxicity, and proliferation. This review provides an update on the intrinsic miRNA regulation of NK cells, including miRNA expression profiles, as well as their impact on NK-cell biology. Additional profiling is needed to better understand miRNA expression within NK-cell developmental intermediates, subsets, tissues, and in the setting of disease. Furthermore, key open questions in the field as well as technical challenges in the study of miRNAs in NK cells are highlighted.
引用
收藏
页码:2862 / 2868
页数:7
相关论文
共 50 条
  • [41] Progress in the treatment of NK-cell lymphoma/leukemia
    Fujimoto, Ayumi
    Suzuki, Ritsuro
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2021, 7
  • [42] INVIVO ENHANCEMENT OF NK-CELL ACTIVITY BY THYMOPENTIN
    HU, C
    RADELLI, L
    SCORZA, R
    BONARA, P
    PEREGO, R
    FANTUZZI, G
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1990, 12 (02): : 193 - 197
  • [43] Extranodal T- and NK-cell lymphomas
    de Leval, Laurence
    Feldman, Andrew L.
    Pileri, Stefano
    Nakamura, Shigeo
    Gaulard, Philippe
    VIRCHOWS ARCHIV, 2023, 482 (01) : 245 - 264
  • [44] NK-cell based delivery of anticancer therapeutics
    Koval, O.
    Volkova, O.
    Kulemzin, S.
    Gorchakov, A.
    Tkachenko, A.
    Nushtaeva, A.
    Kuligina, E.
    Richter, V.
    Taranin, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] NK-cell activity in immunotoxicity drug evaluation
    Cederbrant, K
    Marcusson-Ståhl, M
    Condevaux, F
    Descotes, J
    TOXICOLOGY, 2003, 185 (03) : 241 - 250
  • [46] Targeting NK-cell checkpoints for cancer immunotherapy
    Muntasell, Aura
    Ochoa, Maria C.
    Cordeiro, Luna
    Berraondo, Pedro
    Lopez-Diaz de Cerio, Ascension
    Cabo, Mariona
    Lopez-Botet, Miguel
    Melero, Ignacio
    CURRENT OPINION IN IMMUNOLOGY, 2017, 45 : 73 - 81
  • [47] NATURAL NK-CELL TARGETS IN THE MOUSE THYMUS
    HANSSON, M
    KARRE, K
    KIESSLING, R
    RODER, J
    ANDERSSON, B
    HAYRY, P
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1979, 10 (04) : 367 - 368
  • [48] NK-CELL LEVELS ASSOCIATED WITH LEUKEMIA TYPE
    PREUSS, T
    LEWIS, RE
    MORRISON, FS
    FILES, J
    PULLEN, J
    CUCHENS, M
    CRUSE, JM
    FEDERATION PROCEEDINGS, 1986, 45 (03) : 630 - 630
  • [49] Unlocking a genetic model of NK-cell transformation
    Dufva, Olli
    BLOOD, 2024, 143 (24) : 2443 - 2444
  • [50] Different checkpoints in human NK-cell activation
    Moretta, L
    Bottino, C
    Pende, D
    Vitale, M
    Mingari, MC
    Moretta, A
    TRENDS IN IMMUNOLOGY, 2004, 25 (12) : 670 - 676